Related Experiment Video
Updated: Jul 28, 2025

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
The Childhood Cancer Data Initiative: Using the Power of Data to Learn From and Improve Outcomes for Every Child and
Joseph A Flores-Toro1, Subhashini Jagu1, Gregory T Armstrong2
1National Cancer Institute, Bethesda, MD.
Insights
The Childhood Cancer Data Initiative (CCDI) enhances pediatric cancer research by creating a data ecosystem for sharing and analysis. This initiative aims to improve outcomes for children and young adults with cancer through data-driven insights.
Area of Science:
- Oncology
- Bioinformatics
- Public Health
Background:
- Pediatric cancer research has improved outcomes, but data sharing challenges hinder progress for specific cancers in children and AYAs.
- Unmet needs persist in pediatric oncology due to fragmented data collection and institutional barriers.
Purpose of the Study:
- To establish a comprehensive data ecosystem for pediatric cancer research through the Childhood Cancer Data Initiative (CCDI).
- To facilitate data collection, sharing, and analysis to improve understanding, survivorship, and therapies for pediatric cancers.
- To create sustainable data resources and workflows for long-term advancement in pediatric cancer research.
Main Methods:
- Launched the Childhood Cancer Data Initiative (CCDI) in 2019 with a $50 million annual federal investment.
- Developing a collaborative data ecosystem to support researchers, clinicians, and patients.
- Implementing initiatives like the Molecular Characterization Initiative for comprehensive patient data.
Main Results:
- CCDI facilitates systematic data collection and sharing across the pediatric cancer research community.
- The initiative provides comprehensive molecular characterization for newly diagnosed pediatric cancers.
- Progress is being made towards building expandable and sustainable data resources.
Conclusions:
- Systematic data sharing through CCDI can significantly advance pediatric cancer research and improve patient outcomes.
- The CCDI model has the potential to transform clinical research and treatment for all cancer patients if successful in pediatric cancers.
- Continued investment and collaboration are crucial for the long-term success and sustainability of data-driven cancer research.
Abstract:
Data-driven basic, translational, and clinical research has resulted in improved outcomes for children, adolescents, and young adults (AYAs) with pediatric cancers. However, challenges in sharing data between institutions, particularly in research, prevent addressing substantial unmet needs in children and AYA patients diagnosed with certain pediatric cancers. Systematically collecting and sharing data from every child and AYA can enable greater understanding of pediatric cancers, improve survivorship, and accelerate development of new and more effective therapies. To accomplish this goal, the Childhood Cancer Data Initiative (CCDI) was launched in 2019 at the National Cancer Institute. CCDI is a collaborative community endeavor supported by a 10-year, $50-million (in US dollars) annual federal investment. CCDI aims to learn from every patient diagnosed with a pediatric cancer by designing and building a data ecosystem that facilitates data collection, sharing, and analysis for researchers, clinicians, and patients across the cancer community. For example, CCDI's Molecular Characterization Initiative provides comprehensive clinical molecular characterization for children and AYAs with newly diagnosed cancers. Through these efforts, the CCDI strives to provide clinical benefit to patients and improvements in diagnosis and care through data-focused research support and to build expandable, sustainable data resources and workflows to advance research well past the planned 10 years of the initiative. Importantly, if CCDI demonstrates the success of this model for pediatric cancers, similar approaches can be applied to adults, transforming both clinical research and treatment to improve outcomes for all patients with cancer.
Related Concept Videos
Cancer Survival Analysis
Treatment Resistant Cancers
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Kaplan-Meier Approach

